CanSino’s COVID-19 vaccine candidate approved for military use in China

Grant Boone
June 29, 2020

Once the vaccine proves its efficacy, 70 million additional doses will be locally produced at Fundacao Oswaldo Cruz, known as Fiocruz, and its Bio-Manguinhos immunology institute at the cost of US$160 million.

Organisations around the world are racing to find ways to treat and prevent the deadly pathogen, which first emerged in the central Chinese city of Wuhan and has since killed over half a million people worldwide.

Over 200 vaccine candidates are at different stages of development and 15 are in human clinical trials, Swaminathan said, adding that there is a hope that vaccines will be ready in 12 -18 months.

Chinese researchers and firms have been allowed to test eight vaccine candidates in humans at home and overseas. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS). Once injected, these viral antigens are expressed in human cells that trigger the body's immune response.

It was not clear how widely the potential vaccine will be used within China's enormous military establishment.

United States consumer watchdog chief can be fired by president, supreme court rules
The ruling eliminates the so-called "for cause" provision in Dodd-Frank but keeps the rest of the law and the agency intact. Roberts' holding that the CFBP structure is unconstitutional was joined by Justices Clarence Thomas, Samuel A.

Elcio Franco, Brazil's No 2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year. AstraZeneca's vaccine candidate was developed by researchers at Oxford University.

Brazil, the nation with the second-highest number of coronavirus cases and deaths, reached a deal with the United Kingdom to produce the Covid-19 vaccine that's been developed by Oxford University and AstraZeneca plc.

None have yet been approved for commercial use against the coronavirus.

According to medical journal The Lancet there have already been more than 1,000 clinical trials on dozens of pharmaceutical treatments for the virus but no totally effective medical intervention has been found.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER